Iovance Biotherapeutics (FRA:2LB) Cyclically Adjusted Book per Share: €2.91 (As of Mar. 2026)


FRA:2LB Iovance Biotherapeutics Inc FRA:2LB
44 GF Score
Price €3.69
GF Value €16.45
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Cyclically Adjusted Book per Share?

Iovance Biotherapeutics FRA:2LB +1.10% 44 Cyclically Adjusted Book per Share is €2.91 as of Mar. 2026. GuruFocus rates FRA:2LB with a GF Score™ of 44/100 and a GF Value™ of €16.45 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Iovance Biotherapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €1.425. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Iovance Biotherapeutics's average Cyclically Adjusted Book Growth Rate was -0.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Iovance Biotherapeutics was 46.30% per year. The lowest was 12.20% per year. And the median was 14.10% per year.

As of today (2026-06-30), Iovance Biotherapeutics's current stock price is €3.685. Iovance Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €2.91. Iovance Biotherapeutics's Cyclically Adjusted PB Ratio of today is 1.27.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Iovance Biotherapeutics was 5.06. The lowest was 0.46. And the median was 1.53.


Iovance Biotherapeutics  (FRA:2LB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Iovance Biotherapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.685/2.91
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Iovance Biotherapeutics was 5.06. The lowest was 0.46. And the median was 1.53.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Iovance Biotherapeutics Cyclically Adjusted Book per Share Related Terms


Iovance Biotherapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Cyclically Adjusted Book per Share Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.28 2.30 3.21 3.36 3.02

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.32 3.01 3.00 3.02 2.91

FRA:2LB vs SNDX, GLUE, TYRA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:2LB
44GF Score
Iovance Biotherapeutics Inc FRA:2LB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Iovance Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.425/330.2130*330.2130
=1.425

Current CPI (Mar. 2026) = 330.2130.

Iovance Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.880 241.018 3.946
201609 2.576 241.428 3.523
201612 2.542 241.432 3.477
201703 2.248 243.801 3.045
201706 1.834 244.955 2.472
201709 1.929 246.819 2.581
201712 1.680 246.524 2.250
201803 2.648 249.554 3.504
201806 2.497 251.989 3.272
201809 2.236 252.439 2.925
201812 3.320 251.233 4.364
201903 3.119 254.202 4.052
201906 2.840 256.143 3.661
201909 2.555 256.759 3.286
201912 2.129 256.974 2.736
202003 1.736 258.115 2.221
202006 4.598 257.797 5.890
202009 4.123 260.280 5.231
202012 3.674 260.474 4.658
202103 3.642 264.877 4.540
202106 3.991 271.696 4.851
202109 3.788 274.310 4.560
202112 3.504 278.802 4.150
202203 3.189 287.504 3.663
202206 2.834 296.311 3.158
202209 2.519 296.808 2.803
202212 2.511 296.797 2.794
202303 2.776 301.836 3.037
202306 2.377 305.109 2.573
202309 2.469 307.789 2.649
202312 2.093 306.746 2.253
202403 2.236 312.332 2.364
202406 2.401 314.175 2.524
202409 2.288 315.301 2.396
202412 2.223 315.605 2.326
202503 2.127 319.799 2.196
202506 1.771 322.561 1.813
202509 1.552 324.800 1.578
202512 1.448 324.054 1.476
202603 1.425 330.213 1.425

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €2.91 mean?
Iovance Biotherapeutics (FRA:2LB) has a Cyclically Adjusted Book per Share of €2.91 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Cyclically Adjusted Book per Share too high?
Iovance Biotherapeutics' current Cyclically Adjusted Book per Share is €2.91. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Cyclically Adjusted Book per Share compare to SNDX and GLUE?
Iovance Biotherapeutics' Cyclically Adjusted Book per Share of €2.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Cyclically Adjusted Book per Share is €2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (FRA:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €16.45, compared to a current price of €3.69 — trading 77.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €2.91. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Iovance Biotherapeutics (FRA:2LB), the current Cyclically Adjusted Book per Share is €2.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (FRA:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.69 is trading 77.6% below its estimated GF Value™ of €16.45. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for FRA:2LB:

  • Cyclically Adjusted Book per Share: €2.91
  • GF Value™: €16.45 vs. price of €3.69 (77.6% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for FRA:2LB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.69
Price
€16.45
GF Value